The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Trump Says He Will Allow States to Import Prescription Drugs to Lower Costs

Trump Says He Will Allow States to Import Prescription Drugs to Lower Costs

November 25, 2019 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON (Reuters)—U.S. President Donald Trump said on Friday, Nov. 22, he will soon release a plan to let Florida and other states import prescription medicines to combat high drug prices. He blasted the Democrat-led U.S. House of Representatives for not going far enough in a drug-pricing bill.

You Might Also Like
  • Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad
  • Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices
  • Rheumatology Champions Call for Lower Prescription Drug Costs, and More in Meeting with Congressional Legislators

“We will soon be putting more options on the table,” Trump wrote in a series of tweets, adding that House Speaker Nancy Pelosi (D-Calif.) “and her Do-Nothing Democrats drug pricing bill doesn’t do the trick.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The tweets were similar to comments the president made on Nov. 15 at a White House event with U.S. Health and Human Services (HHS) Sec. Alex Azar, among other officials. At that meeting, Trump said he would work with Florida Gov. Ron DeSantis on a plan to broaden rules on importing pharmaceuticals into this country.

Drug companies have staunchly opposed such a plan, which has been mulled for years, but never implemented.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“House Republicans are showing real LEADERSHIP and prepared to enact bipartisan solutions for drug prices. Do Nothing Democrats are playing partisan politics with YOUR drug prices! We are READY to work together if they actually want to get something done!,” the President, who faces impeachment by the Democrat-led House of Representatives, said on Twitter.

U.S. prescription drug costs are the highest in the developed world because most other countries negotiate pricing directly with manufacturers, while drug companies are allowed to set their own prices in the United States.

Lowering healthcare costs for U.S. consumers is expected to be a major issue in the 2020 presidential campaign.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Drug Updates Tagged With: costs, drug cost, Trump administration

You Might Also Like:
  • Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad
  • Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices
  • Rheumatology Champions Call for Lower Prescription Drug Costs, and More in Meeting with Congressional Legislators
  • Trump Seeks to Base Medicare Drug Prices on Lower Overseas Rates

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)